Histone-lysine N-methyltransferase EZH2 (120-128)

Histone-lysine N-methyltransferase EZH2 (120-128) is a synthetic peptide fragment corresponding to amino acids 120 through 128 of the EZH2 protein, a key enzymatic component of the Polycomb Repressive Complex 2 (PRC2). As a critical regulator of chromatin structure and gene expression, EZH2 mediates the methylation of histone H3 at lysine 27, resulting in gene silencing and epigenetic modulation. The 120-128 region of EZH2 is located within a functionally relevant domain that contributes to protein-protein interactions and the structural integrity of the enzyme. Researchers value this peptide for its utility in dissecting the biochemical properties of EZH2, mapping protein interactions, and advancing the understanding of epigenetic regulation in various biological systems.

Epigenetic research: The EZH2 (120-128) peptide serves as a valuable tool for studying the mechanisms of histone methylation and its impact on chromatin dynamics. By providing a defined segment of the EZH2 protein, it enables the investigation of how specific residues within this region contribute to the methyltransferase's catalytic activity and its recruitment to chromatin substrates. Such studies are essential for unraveling the molecular basis of gene silencing and the broader role of Polycomb group proteins in epigenetic regulation.

Protein-protein interaction assays: As a representative fragment of EZH2, this peptide is frequently employed in binding studies to identify and characterize interaction partners specific to the 120-128 region. Pull-down assays, surface plasmon resonance, and other biophysical techniques can utilize the peptide to elucidate how PRC2 components, regulatory proteins, or small molecules recognize and bind to this segment. Insights gained from these assays inform the design of modulators that target EZH2's functional interfaces.

Antibody validation and epitope mapping: The defined sequence of the EZH2 (120-128) peptide makes it an ideal standard for validating the specificity of antibodies raised against EZH2 or related histone methyltransferases. Researchers can use the peptide in ELISA, Western blot, or immunoprecipitation experiments to confirm antibody binding and map epitopes within the 120-128 region. Accurate antibody validation is crucial for downstream applications in chromatin immunoprecipitation and other immunoassays.

Peptide-based inhibitor screening: The availability of this peptide fragment facilitates the screening and characterization of small molecules or peptides that may inhibit the interaction between EZH2 and its binding partners. By serving as a competitive substrate or binding probe, the peptide supports the identification of compounds that modulate EZH2 function, which is of interest for understanding the regulation of PRC2 activity in physiological and pathological contexts.

Structural biology studies: The EZH2 (120-128) peptide is also utilized in structural analyses aimed at elucidating the conformational features of the enzyme's functional domains. Through approaches such as NMR spectroscopy or X-ray crystallography, the peptide can be incorporated into larger complexes or studied in isolation to reveal secondary structure elements, folding patterns, and interaction motifs. These structural insights contribute to a deeper understanding of EZH2's role in chromatin remodeling and its potential as a target for chemical biology research.

1. Myotropic activity of allatostatins in tenebrionid beetles

2. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I

3. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors